The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | Current treatment landscape in classical MPNs
The treatment landscape for myeloproliferative neoplasms (MPNs) is constantly evolving, as Ruben Mesa, MD, of UT Health San Antonio Cancer Center, San Antonio, TX, explains in this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. He discusses new standardized guidelines for managing MPN patients, and controlling the symptoms and risk of thrombosis. He also gives an overview of the newest clinical trial developments in the field, mentioning the use of ruxolitinib in both polycythemia vera and myelofibrosis, before finally highlighting the potential for combining ruxolitinib with PI3K inhibitors for more effective treatment.
